In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

NovaBay Pharmaceuticals, Inc.. Trade Record

AMEX:NBY NovaBay Pharmaceuticals, Inc. stock gains 15.16% Exit Jun 11, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart NBY Jun 10, 2019, priceSeries
About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
88.97
Entry Date
Jun 10, 2019
Entry Price
3.10
Sell Date
Jun 11, 2019
Sell Price
3.57
Net Gain
15.16%
Hold Time
1 Trading Days